

प्रेषक,

शत्रुन्जय कुमार सिंह,  
विशेष सचिव,  
उत्तर प्रदेश शासन।

सेवा में,

- 1- महानिदेशक, चिकित्सा एवं स्वास्थ्य सेवायें, उ०प्र० लखनऊ।
- 2- महानिदेशक, चिकित्सा शिक्षा एवं प्रशिक्षण, उ०प्र० लखनऊ।

चिकित्सा अनुभाग-5

लखनऊ; दिनांक: 12 अप्रैल, 2020

विषय:-हाईड्राक्सी-क्लोरोक्वीन औषधि का कोविड-19 के रोगियों के उपचार में प्रयोग किए जाने हेतु संस्तुति।

महोदय,


कृपया उपर्युक्त विषय के सम्बन्ध में सचिव, स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय एवं महानिदेशक, आई सी एम आर के पत्र संख्या-वी०आई०आर०/4/2020/ई०सी०डी०-1 दिनांक 22.03.2020 (छायाप्रति संलग्न) का अवलोकन करने का कष्ट करें।

2- संदर्भित पत्र में हाईड्राक्सी-क्लोरोक्वीन औषधि का कोविड-19 के रोगियों के उपचार में प्रयोग किए जाने हेतु नेशनल टास्कफोर्स फॉर कोविड-19 की संस्तुति प्रेषित की गयी है तथा अवगत कराया गया है कि उक्त संस्तुति दिनांक 21.03.2020 की संस्तुति को अवकमित करेगी।

3- कृपया तदनुसार हाईड्राक्सी-क्लोरोक्वीन औषधि का कोविड-19 के रोगियों के उपचार में प्रयोग किए जाने हेतु नेशनल टास्कफोर्स फॉर कोविड-19 की संस्तुति के सम्बन्ध में आवश्यक कार्यवाही करने कष्ट करें।

संलग्नक-यथोक्त।

भवदीय,



( शत्रुन्जय कुमार सिंह )

विशेष सचिव।

संख्या- 842(1)/पांच-5-2020, तददिनांक

प्रतिलिपि निम्नलिखित को सूचनार्थ एवं आवश्यक कार्यवाही हेतु प्रेषित:-

1. निजी सचिव, प्रमुख सचिव/विशेष सचिव, चिकित्सा शिक्षा विभाग, उ०प्र० शासन,
2. निदेशक, संचारी रोग, उ०प्र०।

संलग्नक-यथोक्त।

आज्ञा से,



( प्राणेश चन्द्र शुक्ल )

उप सचिव।

842/वीर-5-200

ANNEXURE I



सत्यमेव जयते

**प्रोफेसर (डा.) बलराम भार्गव**, पद्म श्री

एमडी, डीएम, एफआरसीपी (जी), एफआरसीपी (ई), एफएसीसी,  
एफएएचए, एफएएमएस, एफएनएस, एफएएससी, एफ.एन.ए., डी.एच.सी.

**सचिव, भारत सरकार**

स्वास्थ्य अनुसंधान विभाग

स्वास्थ्य एवं परिवार कल्याण मंत्रालय एवं

महानिदेशक, आई सी एम आर

**Prof. (Dr.) Balram Bhargava**, Padma Shri

MD, DM, FRCP (Glasg.), FRCP (Edin.),  
FACC, FAHA, FAMS, FNAsc, FASc, FNA, DSc

**Secretary to the Government of India**

Department of Health Research  
Ministry of Health & Family Welfare &  
**Director-General, ICMR**



**icmr**  
INDIAN COUNCIL OF  
MEDICAL RESEARCH  
Serving the nation since 1911

**भारतीय आयुर्विज्ञान अनुसंधान परिषद**

स्वास्थ्य अनुसंधान विभाग

स्वास्थ्य एवं परिवार कल्याण मंत्रालय

भारत सरकार

वी. रामलिंगस्वामी भवन, अंसारी नगर

नई दिल्ली - 110 029

**Indian Council of Medical Research**

Department of Health Research

Ministry of Health & Family Welfare

Government of India

V. Ramalingaswami Bhawan, Ansari Nagar

New Delhi - 110 029

**D.O.No.VIR/4/2020/ECD-I**

22<sup>nd</sup> March, 2020

Dear Madam

Please find attached the final recommendation of the National Taskforce for COVID-19 for the use of hydroxychloroquine as prophylaxis. This recommendation supersedes the earlier recommendation dated 21.3.2020

With regards

Yours sincerely,

(Balram Bhargava)

**Encl: As above**

**Smt. Preeti Sudan,**  
Secretary (Health & Family Welfare)  
Ministry of Health & Family Welfare,  
Nirman Bhawan,  
New Delhi-110008.

अप्रिंक  
12.04.2020



### Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection

The National Task force for COVID-19 constituted by Indian Council of Medical Research recommends the use of hydroxy-chloroquine for prophylaxis of SARS-CoV-2 infection for high risk population. Copy is annexed.

The Advisory provides for placing the following high risk population under chemoprophylaxis with hydroxy chloroquine:

- Asymptomatic Healthcare Workers involved in the care of suspected or confirmed cases of COVID-19
- Asymptomatic household contacts of laboratory confirmed cases

The protocol recommended by the National Task force has been approved by the Drug Controller General of India for restricted use in emergency situations.

While following the above recommendations, States should take note of the following:

- 1) **The placing of healthcare workers under chemoprophylaxis should not instill a sense of false security.** They should follow all prescribed public health measures such as frequent washing of hands, respiratory etiquettes, keeping a distance of minimum 1m and use of Personal protective equipment (wherever applicable).
- 2) They should self-monitor their health and report to health authorities immediately in the event of them becoming symptomatic.
- 3) The high risk contacts of a positive case placed under chemo prophylaxis, **should remain in home quarantine while on prophylactic therapy.**
- 4) As recommended by the said Task Force, the drug should only be given on the prescription of a registered medical practitioner. The contraindications mentioned in the recommendations should strictly be followed.
- 5) Apart from the symptoms of COVID-19 (fever, cough, breathing difficulty), if the person on chemo-prophylaxis develops any other symptoms, he should immediately seek medical treatment of the medical practitioner who has prescribed the chemoprophylaxis.

**It is reiterated that the intake of the above medicine should not in still sense of false security.**

## Recommendation for empiric use of hydroxy-chloroquine for prophylaxis of SARS-CoV-2 infection

### **Background:**

Hydroxy-chloroquine is found to be effective against coronavirus in laboratory studies and in-vivo studies. Its use in prophylaxis is derived from available evidence of benefit as treatment and supported by pre-clinical data. The following recommendation for the use of hydroxy-chloroquine as a prophylactic agent against SARS-CoV-2 infection is based on these considerations, as well as risk-benefit consideration, under exceptional circumstances that call for the protection of high-risk individuals.

The National Taskforce for COVID-19 recommends the use of hydroxy-chloroquine for prophylaxis of SARS-CoV-2 infection for selected individuals as follows:

### **Eligible Individuals:**

- Asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19
- Asymptomatic household contacts of laboratory confirmed cases

### **Dose:**

- Asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19: 400 mg twice a day on Day 1, followed by 400 mg once weekly for next 7 weeks; to be taken with meals
- Asymptomatic household contacts of laboratory confirmed cases: 400 mg twice a day on Day 1, followed by 400 mg once weekly for next 3 weeks; to be taken with meals

### **Exclusion/contraindications:**

- The drug is not recommended for prophylaxis in children under 15 years of age.
- The drug is contraindicated in persons with known case of retinopathy, known hypersensitivity to hydroxychloroquine, 4-aminoquinoline compounds

### **Key considerations:**

- The drug has to be given only on the prescription of a registered medical practitioner.
- Advised to consult with a physician for any adverse event or potential drug interaction before initiation of medication
- The prophylactic use of hydroxychloroquine to be coupled with the pharmacovigilance for adverse drug reactions through self-reporting using the Pharmacovigilance Program of India (PvPI) helpline/app.
- If anyone becomes symptomatic while on prophylaxis he/she should immediately contact the health facility, get tested as per national guidelines and follow the standard treatment protocol.
- All asymptomatic contacts of laboratory confirmed cases should remain in home quarantine as per the national guidelines, even if they are on prophylactic therapy.
- Simultaneously, proof of concept and pharmacokinetics studies be taken up expeditiously. Findings from these studies and other new evidence will guide any change in the recommendation.